195 related articles for article (PubMed ID: 34218217)
1. Interleukin-2 therapy of cancer-clinical perspectives.
Majidpoor J; Mortezaee K
Int Immunopharmacol; 2021 Sep; 98():107836. PubMed ID: 34218217
[TBL] [Abstract][Full Text] [Related]
2. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy With Low-Dose IL-2 in Combination With GM-CSF.
Mier JW
J Immunother; 2003; 26(2):95-6. PubMed ID: 12616100
[No Abstract] [Full Text] [Related]
5. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy comes of age.
Rosenberg SA
Nat Clin Pract Oncol; 2005 Mar; 2(3):115. PubMed ID: 16264884
[No Abstract] [Full Text] [Related]
7. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.
Ridolfi L; de Rosa F; Ridolfi R; Gentili G; Valmorri L; Scarpi E; Parisi E; Romeo A; Guidoboni M
J Transl Med; 2014 Sep; 12():262. PubMed ID: 25245327
[TBL] [Abstract][Full Text] [Related]
8. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
9. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
Dhupkar P; Gordon N
Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
[TBL] [Abstract][Full Text] [Related]
11. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy.
Sherry RM; Pass HI; Rosenberg SA; Yang JC
Cancer; 1992 Apr; 69(7):1850-5. PubMed ID: 1551067
[TBL] [Abstract][Full Text] [Related]
12. Keynote address: perspectives on the use of interleukin-2 in cancer treatment.
Rosenberg SA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S2-6. PubMed ID: 9457385
[No Abstract] [Full Text] [Related]
13. Despite past disappointments, the future of melanoma therapy appears bright.
Tarhini A
Oncology (Williston Park); 2009 May; 23(6):509, 515. PubMed ID: 19544692
[No Abstract] [Full Text] [Related]
14. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12).
Merad M; Angevin E; Wolfers J; Flament C; Lorenzi I; Triebel F; Escudier B; Zitvogel L
J Immunother; 2000; 23(3):369-78. PubMed ID: 10838666
[TBL] [Abstract][Full Text] [Related]
15. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
16. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
Marabondo S; Kaufman HL
Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
18. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
19. The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.
Baars JW; Hack CE; Wagstaff J; Eerenberg-Belmer AJ; Wolbink GJ; Thijs LG; Strack van Schijndel RJ; van der Vall HL; Pinedo HM
Br J Cancer; 1992 Jan; 65(1):96-101. PubMed ID: 1733448
[TBL] [Abstract][Full Text] [Related]
20. The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma.
Romo de Vivar Chavez A; de Vera ME; Liang X; Lotze MT
Med Oncol; 2009; 26 Suppl 1():3-12. PubMed ID: 19148593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
